$32m financing takes EsophyX closer to launch
This article was originally published in Clinica
Executive Summary
EndoGastric Solutions' (EGS) EsophyX device for the incisionless surgical treatment of gastroesophageal reflux disease (GERD) is another step closer to market, after the company raised $32m in a series C financing round. Venture capital firm Chicago Growth Partners was the lead investor.